NASDAQ (NDAQ) Announces Changes to the Nasdaq-100 Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq touch new peaks as Treasury yields cool, oil slips
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Nasdaq notches record high close as investors focus on earnings
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Trip.com Group (TCOM) Reports Q3 EPS of $0.13
December 15, 2021 5:03 PM ESTTrip.com Group (NASDAQ: TCOM) reported Q3 EPS of $0.13. Revenue for the quarter came in at $831 million.
For earnings history and earnings-related data on Trip.com Group (TCOM) click here.
... MoreIncyte (INCY) Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream as a Treatment for Patients with Vitiligo
December 14, 2021 4:31 PM ESTIncyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura) a topical JAK inhibitor, as a potential treatment for adolescents and adults (age 12 years) with vitiligo. The FDA grants Priority Review to medicines that may offer a major advance in treatment where none currently exists. The Prescription Drug User... More



